Literature DB >> 17053026

Porcine somatostatin receptor 2 displays typical pharmacological sst2 features but unique dynamics of homodimerization and internalization.

Mario Durán-Prado1, Christine Bucharles, Bruno J Gonzalez, Rafael Vázquez-Martínez, Antonio J Martínez-Fuentes, Socorro García-Navarro, Simon J Rhodes, Hubert Vaudry, María M Malagón, Justo P Castaño.   

Abstract

Somatostatin (SRIF) exerts its multiple actions, including inhibition of GH secretion and of tumoral growth, through a family of five receptor subtypes (sst1-sst5). We recently reported that an sst2-selective agonist markedly decreases GH release from pig somatotropes, suggesting important roles for this scarcely explored receptor, psst2. Here, functional expression of psst2 in Chinese hamster ovary-K1 and human embryonic kidney-293-AD cell lines was employed to determine its pharmacological features and functional ability to reduce cAMP, and to examine its homodimerization and internalization dynamics in real time in single living cells. Results show that psst2 is a high-affinity receptor (dissociation constant = 0.27 nM) displaying a typical sst2 profile (nM affinity for SRIF-14> or =SRIF-28>cortistatin>MK678>octreotide) and high selectivity (EC(50) = 1.1 nM) for the sst2 agonist l-779,976, but millimolar or undetectable affinity to other sst-specific agonists (sst3>sst1>sst5>>>sst4). Accordingly, SRIF dose-dependently inhibited forskolin-stimulated cAMP with high potency (EC(50) = 6.55 pm) and modest efficacy (maximum 29.1%) via psst2. Cotransfection of human embryonic kidney-293 and Chinese hamster ovary-K1 cells with two receptor constructs modified with distinct fluorescent tags (psst2-YFP/psst2-CFP) enabled fluorescence resonance energy transfer measurement of physical interaction between psst2 receptors and also receptor internalization in single living cells. This revealed that under basal conditions, psst2 forms constitutive homodimers/homomultimers, which dissociate immediately (11 sec) upon SRIF binding. Interestingly, contrary to human sst2, psst2 rapidly reassociates (110.5 sec) during a subsequent process that temporally overlaps with receptor internalization (half-maximal = 95.1 sec). Therefore, psst2 is a potent inhibitory receptor displaying a unique set of interrelated dynamic features of agonist-dependent dimerization, dissociation, internalization, and reassociation, a cascade of events that might be critical for receptor function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17053026     DOI: 10.1210/en.2006-0920

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  12 in total

1.  Discrimination between alternate membrane protein topologies in living cells using GFP/YFP tagging and pH exchange.

Authors:  Beatriz Domingo; María Gasset; Mario Durán-Prado; Justo P Castaño; Antonio Serrano; Thierry Fischer; Juan Llopis
Journal:  Cell Mol Life Sci       Date:  2010-05-08       Impact factor: 9.261

Review 2.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

Review 3.  Cross-talk and modulation of signaling between somatostatin and growth factor receptors.

Authors:  Ujendra Kumar
Journal:  Endocrine       Date:  2011-08-26       Impact factor: 3.633

4.  Identification of critical residues involved in ligand binding and G protein signaling in human somatostatin receptor subtype 2.

Authors:  Jesse J Parry; Ronald Chen; Rebecca Andrews; Kimberly A Lears; Buck E Rogers
Journal:  Endocrinology       Date:  2012-04-11       Impact factor: 4.736

5.  Microarray analysis of somatostatin receptor 5-regulated gene expression profiles in murine pancreas.

Authors:  Sanjeet G Patel; Guisheng Zhou; Shi-He Liu; Min Li; Jae-Wook Jeong; Francesco J DeMayo; Marie-Claude Gingras; Richard A Gibbs; William E Fisher; F Charles Brunicardi
Journal:  World J Surg       Date:  2009-04       Impact factor: 3.352

6.  Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents.

Authors:  Jose Córdoba-Chacón; Manuel D Gahete; Mario Duran-Prado; Ana I Pozo-Salas; María M Malagón; F Gracia-Navarro; Rhonda D Kineman; Raul M Luque; Justo P Castaño
Journal:  Cell Mol Life Sci       Date:  2010-04       Impact factor: 9.261

7.  Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization.

Authors:  Michael Grant; Haydar Alturaihi; Philippe Jaquet; Brian Collier; Ujendra Kumar
Journal:  Mol Endocrinol       Date:  2008-07-24

8.  Pathophysiology of GPCR Homo- and Heterodimerization: Special Emphasis on Somatostatin Receptors.

Authors:  Rishi K Somvanshi; Ujendra Kumar
Journal:  Pharmaceuticals (Basel)       Date:  2012-04-27

Review 9.  Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways.

Authors:  Mehtap Cakir; Dorota Dworakowska; Ashley Grossman
Journal:  J Cell Mol Med       Date:  2010-11       Impact factor: 5.310

Review 10.  Down-regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5: a novel mechanism for inhibition of cellular proliferation and insulin secretion by somatostatin.

Authors:  Guisheng Zhou; Jim Sinnett-Smith; Shi-He Liu; Juehua Yu; James Wu; Robbi Sanchez; Stephen J Pandol; Ravinder Abrol; John Nemunaitis; Enrique Rozengurt; F Charles Brunicardi
Journal:  Front Physiol       Date:  2014-06-25       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.